Silencing of eIF3e promotes blood perfusion recovery after limb ischemia through stabilization of hypoxia-inducible factor 2α activity

详细信息    查看全文

• 作者：Takuya Hashimoto ; MD ; PhD^a ; Li Chen ; PhD^b ; Hideo Kimura ; MD ; PhD^a ; Alexander Endler ; PhD^b ; Hiroyuki Koyama ; MD ; PhD^a ; ^c ; ^d ; ^{hkoyama-tky@umin.ac.jp" class="auth_mail" title="E-mail the corresponding author} ; Tetsuro Miyata ; MD ; PhD^e ; Futoshi Shibasaki ; MD ; PhD^b ; Toshiaki Watanabe ; MD ; PhD^a
• 刊名：Journal of Vascular Surgery
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：64
• 期：1
• 页码：219-226.e3
• 全文大小：1487 K

文摘

We previously observed that silencing of eukaryotic translation initiation factor 3 subunit e (eIF3e), a hypoxia-independent downregulator of hypoxia-inducible factor 2α (HIF-2α), led to neoangiogenesis by promoting HIF-2α activity under normoxic conditions. In the current study, we investigated whether temporary silencing of eIF3e in muscles affects blood flow recovery in a mouse ischemic limb model.

Methods

eIF3e silencing was performed using small interfering RNA (siRNA), and changes in gene transcription and protein expression were analyzed in vitro using murine primary skeletal muscle myoblast and human primary skeletal muscle myoblast cell cultures. In unilateral femoral artery ligation experiments, eIF3e siRNA-expressing plasmids were injected into the muscles of BALB/c mice near the ligation sites, and tissue damage and loss of limb function were scored for 28 days while serial measurements of limb perfusions were performed with laser Doppler perfusion imaging.

Results

Silencing of eIF3e in murine primary skeletal muscle myoblasts led to stabilization of HIF-2α and upregulation of angiogenic transcripts, including basic fibroblast growth factor and platelet-derived growth factor B (P < .05), and the supernatant of eIF3e-silenced human primary skeletal muscle myoblasts triggered the tube formation of human umbilical vein endothelial cells. The in vivo mouse model of hindlimb ischemia revealed that single intramuscular injections of eIF3e siRNA-expressing plasmids significantly enhanced perfusion of ischemia-damaged limbs (P < .05) at days 7 and 14 and functional recovery at days 7, 14, and 21 (P < .05).

Conclusions

eIF3e is an angiogenesis suppressor and may be a therapeutic target for promoting angiogenesis after ischemic injuries.